Outcome in intermediate or high risk prostate cancer patients receiving radiation dose and hormone therapy

Acta Oncologica

Volumn 48, Issue 6, 2009, Pages 874-881

  Karlsdóttir, Ása ^a,b   Muren, Ludvig Paul ^b,c   Wentzel Larsen, Tore ^b   Johannessen, Dag C ^b   Haukaas, Svein Andreas ^a,b   Halvorsen, Ole Johan ^d   Dahl, Olav ^a,b  

^a UNIVERSITY OF BERGEN   (Norway)

^b HAUKELAND UNIVERSITY HOSPITAL   (Norway)

^c AARHUS UNIVERSITY HOSPITAL   (Denmark)

^d HAUKELAND UNIVERSITY HOSPITAL   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIANDROGEN; GONADORELIN; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ANDROGEN DEPRIVATION THERAPY; ARTICLE; CANCER GRADING; CANCER PATIENT; CANCER RECURRENCE; CANCER SURVIVAL; CONTROLLED STUDY; EXTERNAL BEAM RADIOTHERAPY; FOLLOW UP; HIGH RISK PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROSTATE CANCER; RADIATION DOSE; TREATMENT FAILURE;

ADENOCARCINOMA; AGED; AGED, 80 AND OVER; ANDROGEN ANTAGONISTS; COMBINED MODALITY THERAPY; GONADOTROPIN-RELEASING HORMONE; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; NEOPLASMS, HORMONE-DEPENDENT; PROGNOSIS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RADIOTHERAPY DOSAGE; RADIOTHERAPY, HIGH-ENERGY; RISK FACTORS; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 70350688146     PISSN: 0284186X     EISSN: 1651226X     Source Type: Journal    
DOI: 10.1080/02841860902974159     Document Type: Article

References (32)

1. Cancer Registry of Norway. Cancer in Norway 2007. Oslo, Norway, 2008.
2. Martinez AA, Gonzalez JA, Chung AK, et al. A comparison of external beam radiation therapy versus radical prostatectomy for patients with low risk prostate carcinoma diagnosed, staged, and treated at a single institution. Cancer 2000;/88:/ 425-32.
3. D'Amico AV, Whittington R, Kaplan I, et al. Equivalent 5- year bNED in select prostate cancer patients managed with surgery or radiation therapy despite exclusion of the seminal vesicles from the CTV. Int J Radiat Oncol Biol Phys 1997;/ 39:/335-40.
4. Bill-Axelso A, Holmberg L, Filen F, et al. Radical prostatectomy versus watchful waiting in localized prostate cancer: The Scandinavian prostate cancer group-4 randomized trial. J Natl Cancer Inst 2008;/100:/1144-54.
5. Karlsdottir A, Muren LP, Wentzel-Larsen T, et al. Radiation dose escalation combined with hormone therapy improves outcome in localised prostate cancer. Acta Oncol 2006;/45:/ 454-62.
6. Hermanek P, Sobin LH, TNM classification of malignant tumours. 4th edn. International Union Against Cancer (UICC) 1992, Berlin, Heidelberg, New York: Springer Verlag.
7. Mostofi FK, Sesterhenn IA, Sobin LH. Histological typing of prostate tumours. Geneva: World Health Organization; 1980.
8. Mellinger GT, Gleason D, Bailar J. The histology and prognosis of prostatic cancer. J Urology 1967;/97:/331-8.
9. Van der Kwast TH, Roobol MJ, Wildhagen MF, et al. Consistency of prostate cancer grading results in screened populations across Europe. BJU Int 2003;/92(Suppl 2):/ 88-91.
10. Karlsdottir A, Johannessen DC, Muren LP, et al. Acute morbidity related to treatment volume during 3D-conformal radiation therapy for prostate cancer. Radiother Oncol 2004;/ 71:/43-53.
11. Roach III M, Hanks G, Thames Jr. H, et al. Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: Recommendations of the RTOG-ASTRO Phoenix Consensus Conference. Int J Radiat Oncol Biol Phys 2006; 65:965-74.
12. Karlsdottir A, Muren LP, Wentzel-Larsen T, et al. Late gastrointestinal morbidity after three-dimensional conformal radiation therapy for prostate cancer fades with time in contrast to genitourinary morbidity. Int J Radiat Oncol Biol Phys 2008;/70:/1478-86.
13. Altman D. Practical statistics for medical research. London, New York: Chapman and Hall; 1991. p 611.
14. Kupelian P, Thames H, Levy L, et al. Year of treatment as independent predictor of relapse-free survival in patients with localized prostate cancer treated with definitive radiotherapy in the PSA era. Int J Radiat Oncol Biol Phys 2005;/ 63:/795-9.
15. Shahinian VB, Kuo YF, Freeman JL, et al. Increasing use of gonadotropin-releasing hormone agonists for the treatment of localized prostate carcinoma. Cancer 2005;/103:/1615-24.
16. Widmark A, Klepp O, Solberg A, et al. Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/SFUO-3): An open randomised phase III trial. Lancet 2009;/373:/301-8.
17. Bolla M, Collette L, Blank L, et al. Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): A phase III randomised trial. Lancet 2002;/360:/ 103-8.
18. Dearnaley DP, Sydes MR, Graham JD, et al. Escalated-dose versus standard-dose conformal radiotherapy in prostate cancer: First results from the MRC RT01 randomised controlled trial. Lancet Oncol 2007;/8:/475-87.
19. Zietman AL, DeSilvio ML, Slater JD, et al. Comparison of conventional-dose vs high-dose conformal radiation therapy in clinically localized adenocarcinoma of the prostate: A randomized controlled trial. JAMA 2005;/294:/1233-9.
20. Pollack A, Zagars GK, Starkschall G, et al. Prostate cancer radiation dose response: Results of the M. D. Anderson phase III randomized trial. Int J Radiat Oncol Biol Phys 2002;/53:/1097-105.
21. Peeters ST, Heemsbergen WD, Koper PC, et al. Doseresponse in radiotherapy for localized prostate cancer: Results of the Dutch multicenter randomized phase III trial comparing 68 Gy of radiotherapy with 78 Gy. J Clin Oncol 2006;/24:/1990-6.
22. Zelefsky MJ, Fuks Z, Hunt M, et al. High dose radiation delivered by intensity modulated conformal radiotherapy improves the outcome of localized prostate cancer. J Urol 2001;/166:/876-81. (Pubitemid 32750970)
23. Klotz LH. Active surveillance for good risk prostate cancer: Rationale, method, and results. Can J Urol 2005;/12(Suppl 2):/21-4.
24. Warlick C, Trock BJ, Landis P, et al. Delayed versus immediate surgical intervention and prostate cancer outcome. J Natl Cancer Inst 2006;/98:/355-7.
25. Bolla M, Gonzalez D, Warde P, et al. Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin. N Engl J Med 1997;/337:/ 295-300.
26. D'Amico AV, Manola J, Loffredo M, et al. 6-month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer: A randomized controlled trial. JAMA 2004;/292:/ 821-7.
27. Denham JW, Steigler A, Lamb DS, et al. Short-term androgen deprivation and radiotherapy for locally advanced prostate cancer: Results from the Trans-Tasman Radiation Oncology Group 96.01 randomised controlled trial. Lancet Oncol 2005;/6:/841-50.
28. Roach M, 3rd, Bae K, Speight J, et al. Short-term neoadjuvant androgen deprivation therapy and externalbeam radiotherapy for locally advanced prostate cancer: Long-term results of RTOG 8610. J Clin Oncol 2008;/26:/ 585-91.
29. Zeliadt SB, Potosky AL, Penson DF, et al. Survival benefit associated with adjuvant androgen deprivation therapy combined with radiotherapy for high- and low-risk patients with nonmetastatic prostate cancer. Int J Radiat Oncol Biol Phys 2006;/66:/395-402.
30. Valicenti R, Bae K, Michalski J, et al. Does adjuvant hormonal therapy improve freedom from biochemical relapse in prostate cancer patients receiving dose-escalated radion therapy? An analysis of RTOG 94-06. Int J Radiat Oncol Biol Phys 2007;/69:/s171.
31. Bolla M, van Tiehoven G, de Reijke TM, et al. Concomitant and adjuvant androgen deprivation (ADT) with external beam irradiation (RT) for locally advanced prostate cancer: 6 months versus 3 years ADT - Results of the randomized EORTC Phase III trial 22961. J Clin Oncol 2007;/25:/s238.
32. McLeod DG, Iversen P, SeeWA, et al. Bicalutamide 150 mg plus standard care vs standard care alone for early prostate cancer. BJU Int 2006;/97:/247-54.